MétaCan
Menu
Back to cohort
Record W2470412971 · doi:10.1038/npjbcancer.2016.22

The molecular landscape of high-risk early breast cancer: comprehensive biomarker analysis of a phase III adjuvant population

2016· article· en· W2470412971 on OpenAlexfundno aff
Timothy R. Wilson, Jianjun Yu, Xuyang Lu, Jill M. Spoerke, Yuanyuan Xiao, Carol O’Brien, Heidi Savage, Ling‐Yuh Huw, Wei Zou, Hartmut Koeppen, William F. Forrest, Jane Fridlyand, Ling Fu, Rachel Tam, Erica Schleifman, Teiko Sumiyoshi, Luciana Molinero, Garret M. Hampton, Joyce O’Shaughnessy, Mark R. Lackner

Bibliographic record

Venuenpj Breast Cancer · 2016
Typearticle
Languageen
FieldMedicine
TopicCancer Immunotherapy and Biomarkers
Canadian institutionsnot available
FundersBC Cancer AgencyCancer Research UK
KeywordsSubtypingBreast cancerOncologyMedicineInternal medicinePopulationCancerCancer research

Abstract

fetched live from OpenAlex

Abstract Breast cancer is a heterogeneous disease and patients are managed clinically based on ER, PR, HER2 expression, and key risk factors. We sought to characterize the molecular landscape of high-risk breast cancer patients enrolled onto an adjuvant chemotherapy study to understand how disease subsets and tumor immune status impact survival. DNA and RNA were extracted from 861 breast cancer samples from patients enrolled onto the United States Oncology trial 01062. Samples were characterized using multiplex gene expression, copy number, and qPCR mutation assays. HR + patients with a PIK3CA mutant tumor had a favorable disease-free survival (DFS; HR 0.66, P =0.05), however, the prognostic effect was specific to luminal A patients (Luminal A: HR 0.67, P =0.1; Luminal B: HR 1.01, P =0.98). Molecular subtyping of triple-negative breast cancers (TNBCs) suggested that the mesenchymal subtype had the worst DFS, whereas the immunomodulatory subtype had the best DFS. Profiling of immunologic genes revealed that TNBC tumors ( n =280) displaying an activated T-cell signature had a longer DFS following adjuvant chemotherapy (HR 0.59, P =0.04), while a distinct set of immune genes was associated with DFS in HR + cancers. Utilizing a discovery approach, we identified genes associated with a high risk of recurrence in HR + patients, which were validated in an independent data set. Molecular classification based on PAM50 and TNBC subtyping stratified clinical high-risk patients into distinct prognostic subsets. Patients with high expression of immune-related genes showed superior DFS in both HR + and TNBC. These results may inform patient management and drug development in early breast cancer.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.001
metaresearch head score (Gemma)0.001
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: Observational
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.001
Threshold uncertainty score0.006

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0010.001
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0000.000
Bibliometrics0.0000.000
Science and technology studies0.0000.000
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0000.000
Insufficient payload (model declined to judge)0.0000.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.010
GPT teacher head0.285
Teacher spread0.275 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designObservational
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations27
Published2016
Admission routes1
Has abstractyes

Explore more

Same venuenpj Breast CancerSame topicCancer Immunotherapy and BiomarkersFrench-language works237,207